Company Profile
Axsome Stock Price, News & Catalysts
- Ticker:
- AXSM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
214.28 USD (+1.09%)
Close
Last updated: September 17, 2026
11.4B USD
Market cap
Why the stock is moving
The latest company update was “Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026”. AXSM changed 1.09% and closed at $214.28 on Sep 17, 2026, indicating a relatively limited closing-price reaction to this company update.
Company overview
CNS Commercial Portfolio
Axsome Therapeutics develops and commercializes medicines for central nervous system disorders. Its business combines marketed products in depression, migraine and sleep disorders with a pipeline spanning psychiatry and neurology.
AUVELITY
AUVELITY is an oral NMDA receptor antagonist and sigma-1 receptor agonist approved for major depressive disorder and agitation associated with dementia due to Alzheimer’s disease. The Alzheimer’s agitation indication expands the product into a second large neuropsychiatric market.
Migraine and Sleep Medicine
SYMBRAVO is an acute migraine treatment, while SUNOSI is approved for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy. Together they diversify Axsome’s commercial base beyond AUVELITY.
AXS-12 and Solriamfetol Development
AXS-12 has been submitted to the FDA for cataplexy in narcolepsy. Solriamfetol is also being developed in pediatric Phase 3 trials for attention-deficit hyperactivity disorder and in the ENGAGE and SUSTAIN programs.
Earlier CNS Pipeline
AXS-05 is planned for pivotal study in smoking cessation. AXS-20, or balipodect, is a Phase 3-ready PDE10A inhibitor being prepared for development in schizophrenia and Tourette syndrome.
Future catalysts
- Initiation of the pivotal Phase 2/3 AXS-05 smoking-cessation trial in the third quarter of 2026.
- Topline results from the Phase 3 ENGAGE study of solriamfetol in binge-eating disorder in the fourth quarter of 2026.
- Topline results from the Phase 3 SUSTAIN study of solriamfetol in shift-work disorder in 2027.
- FDA action on the AXS-12 NDA for cataplexy in narcolepsy by the May 1, 2027 PDUFA date.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Axsome (AXSM)?
Axsome (AXSM) most recently closed at 214.28 USD, a +1.09% move versus the previous session.
What is the market cap of Axsome (AXSM)?
Axsome currently has a market capitalization of 11.4B USD on BioPharmSignal.
What does Axsome do?
CNS Commercial Portfolio Axsome Therapeutics develops and commercializes medicines for central nervous system disorders. Its business combines marketed products in depression, migraine and sleep disorders with a pipeline spanning psychiatry and neurology. AUVELITY AUVELITY is an oral NMDA receptor antagonist and sigma-1 receptor agonist approved for major...
On which exchange is AXSM stock listed?
Axsome (AXSM) is associated with NASDAQ, United States, Biopharma.
What is AXS-12?
FDA action on the AXS-12 NDA for cataplexy in narcolepsy by the May 1, 2027 PDUFA date.
Which conditions is Axsome targeting with AXS-12?
Axsome is associated with neurology based on its company overview and current catalyst commentary.
How does Axsome describe recent progress with AXS-12?
FDA action on the AXS-12 NDA for cataplexy in narcolepsy by the May 1, 2027 PDUFA date.
What is AXS-05?
Earlier CNS Pipeline AXS-05 is planned for pivotal study in smoking cessation.